Analyst provides a high price target for Viking Therapeutics stock.
1 report, 1 independent
Updated Sep 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst provides a high price target for Viking Therapeutics stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Viking Therapeutics
company in San Diego, United States
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.
- Tenax Therapeutics listed on Nasdaq and received research reports from Cantor Fitzgerald, attracting investment from ADAR1 Capital Management.
- Cantor Fitzgerald lifted its price target for ARS Pharmaceuticals, Inc. on June 1, 2026.
- Cantor Fitzgerald raised its price target on Texas Instruments shares on July 8, 2026.